About us
Ipsen was first established as a business in the UK in 1981, and in Ireland in 1989. Today, the UK & Ireland forms a critical and growing part of our Global network and is one of our core operating hubs alongside Cambridge, M.A., USA and Paris, France. As a UK & Ireland Hub we are collaborating to deliver outcomes for patients, health services and our community of current and future colleagues. Three of Ipsen’s leading medicines are manufactured in the UK & Ireland, with our UK footprint also ‘home’ to the global neuroscience franchise, with neurotoxin research, development, and manufacturing capabilities located across our Milton Park (Oxford) and Wrexham facilities.
Therapeutic areas
Ipsen’s vision is to be a leading global mid-size biopharmaceutical company, with a focus on transformative medicines in three key therapeutic areas: oncology, rare disease and neuroscience. We provide innovative solutions for disabling conditions to improve patient care.
Therapeutic areasOur medicines
Learn more about our medicines and the policies we have in place to continuously evaluate their efficacy and safety.
Our medicinesClinical trials
Working with leading clinical centres across the UK and Ireland, Ipsen’s research focuses on oncology, neuroscience and rare diseases, investigating new compounds and increasing understanding of our licensed medicines.
Effectively gathering data
Ipsen, is committed to ensuring we bring therapies through clinical development in a way that is robust, practical and ethical.
In the UK we work with clinical centres and the NHS to test our experimental and existing therapies. Our researchers are striving to advance science as quickly as possible to deliver solutions and improve patient outcomes in our key focus areas; oncology, neuroscience and rare diseases.
Current clinical studies Ipsen UK & Ireland are running:
If you are a healthcare professional with a query about an Ipsen clinical trial, please contact medinfo.uk-ie@ipsen.com
If you are a patient, or a family member or carer of a patient, and have a question about an Ipsen clinical study, then we advise that you first speak to your doctor. They will then be able to contact us, if required, with the detail and background of your query.
Details of all registered clinical trials are also available on the website www.clinicaltrials.gov
Learn more
Report Adverse Events
Adverse events should be reported.
In the UK
Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store.
Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on 01753 627777
In Ireland
Reporting forms and information can be found at https://www.hpra.ie/ or e-mail medsafety@hpra.ie. The HPRA can also be contacted on +353 16764971.
Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone 01753 627777 (IE phone: +353 1 8098256)
Ipsen Careers in the UK & Ireland
Hiring and retaining talented individuals is key to Ipsen’s success. Joining Ipsen means being part of a dynamic and innovation-driven Group which offers motivating challenges and a wealth of opportunities.
Ipsen UK & Ireland careersCRSC-GB-000098
November 2023
